## Going beyond commitment,

【】 SUVEN LIFE SCIENCES LTD
Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034 CIN: L24110TG1989PLC009713 Tel: 91402354 1142/ 3311/ 3315 Fax: 914023541152 Email: investorservices@suven.com website: www.suven.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014

| PART - I |  | Rs. in lakhs |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| SI. No. | PARTICULARS | Quarter ended |  |  | Previous year |
|  |  | 30/06/2014 | 31/03/2014 | 30/06/2013 | 31/03/2014 |
|  |  | Un-audited | Audited | Un-audited | Audited |
| 1 | Income from operations <br> (a) Net sales/income from operations (Net of excise duty) <br> (b) Other operating income | $14,153.16$ | $13,080.34$ | $10,866.96$ | $51,031.24$ |
|  | Total income from operations (net) (a)+(b) | 14,153.16 | 13,080.34 | 10,866.96 | 51,031.24 |
| 2 | Expenses <br> a) Cost of materials consumed <br> b) Purchases of stock-in-trade <br> c) Changes in inventories of finished goods, work-in-progress and stock-in-trade <br> d) Employee benefits expense <br> e) Depreciation and amortisation expense <br> f) Other expenses - Manufacturing Expenses <br> - R \& D Expenses <br> - Others | $\begin{gathered} 4,695.34 \\ - \\ (47.88) \\ 911.37 \\ 238.86 \\ 1,439.61 \\ 894.89 \\ 471.67 \end{gathered}$ | $\begin{gathered} 3,898.42 \\ - \\ 339.57 \\ 710.62 \\ 227.51 \\ 1,600.29 \\ 1,238.05 \\ 549.70 \end{gathered}$ | $\begin{array}{r} 3,374.55 \\ - \\ 14.69 \\ 779.83 \\ 209.48 \\ 1,159.51 \\ 793.87 \\ 441.32 \end{array}$ | $\begin{gathered} 15,049.65 \\ - \\ (1,397.66) \\ 3,144.21 \\ 883.74 \\ 5,388.94 \\ 4,794.79 \\ 2,145.45 \end{gathered}$ |
|  | Total expenses | 8,603.86 | 8,564.16 | 6,773.25 | 30,009.12 |
| 3 4 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) <br> Other Income | $\begin{array}{r} 5,549.30 \\ 107.94 \end{array}$ | $\begin{array}{r} 4,516.18 \\ 120.29 \end{array}$ | $\begin{array}{r} 4,093.71 \\ 315.53 \end{array}$ | $\begin{array}{r} 21,022.12 \\ 302.95 \end{array}$ |
| 5 6 | Profit / (Loss) from ordinary activities before finance costs and exceptional items $(3+4)$ <br> Finance costs | $\begin{array}{r} 5,657.24 \\ 116.42 \end{array}$ | $\begin{array}{r} 4,636.47 \\ 169.51 \end{array}$ | $\begin{array}{r} 4,409.24 \\ 319.06 \end{array}$ | $\begin{array}{r} 21,325.07 \\ 1,051.28 \end{array}$ |
| $\begin{aligned} & 7 \\ & 8 \end{aligned}$ | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) <br> Exceptional Items | $\begin{array}{r} 5,540.82 \\ 405.99 \end{array}$ | $4,466.96$ | $4,090.18$ | $20,273.79$ |
| $\begin{gathered} 9 \\ 10 \end{gathered}$ | Profit/Loss from Ordinary Activities before tax (7) 8) <br> Tax Expenses | $\begin{aligned} & 5,134.83 \\ & 1,661.01 \end{aligned}$ | $\begin{aligned} & 4,466.96 \\ & 1,226.40 \end{aligned}$ | $\begin{aligned} & 4,090.18 \\ & 1,112.99 \end{aligned}$ | $\begin{array}{r} 20,273.79 \\ 5,858.04 \end{array}$ |
| $\begin{aligned} & 11 \\ & 12 \end{aligned}$ | Net Profit/ (Loss) from Ordinary Activities after tax (9-10) Extraordinary Items (net of tax expense Rs $\qquad$ _) | $3,473.82$ | $3,240.56$ | 2,977.19 | 14,415.75 |
| 13 | Net Profit / (Loss) for the period (11 + 12) | 3,473.82 | 3,240.56 | 2,977.19 | 14,415.75 |
| 14 | Share of profit / (loss) of associates | - | - | - | - |
| 15 | Minority interest | - | - | - | - |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates ( $13+14+15$ ) | 3,473.82 | 3,240.56 | 2,977.19 | 14,415.75 |
| 17 | Paid-up equity share capital (Face Value of Rs. 1/- each) | 1,168.29 | 1,168.29 | 1,168.29 | 1,168.29 |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | - | - | - | 25,276.34 |
| 19.i | Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised): <br> a) Basic <br> b) Diluted | $\begin{aligned} & 2.97 \\ & 2.97 \end{aligned}$ | 2.77 2.77 | 2.55 2.55 | $\begin{aligned} & 12.34 \\ & 12.34 \end{aligned}$ |
| 19.ii | Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised): <br> a) Basic <br> b) Diluted | $\begin{aligned} & 2.97 \\ & 2.97 \end{aligned}$ | 2.77 2.77 | 2.55 2.55 | 12.34 12.34 |
|  |  |  |  |  |  |



| SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | PARTICULARS | Quarter ended |  |  | Previous year ended |
|  |  | 30/06/2014 | 31/03/2014 | 30/06/2013 | 31/03/2014 |
|  |  | Un-audited | Audited | Un-audited | Audited |
|  | SEGMENT REVENUE <br> a) Manufacturing (CRAMS) <br> b) Services (DDDSS) <br> c) Research \& Development | $\begin{array}{r} 13,894.85 \\ 258.21 \end{array}$ | $\begin{array}{r} 12,683.57 \\ 396.78 \end{array}$ | $\begin{array}{r} 10,688.52 \\ 178.43 \end{array}$ | $\begin{array}{r} 49,344.00 \\ 1,687.24 \end{array}$ |
|  | Net sales/income from operations | 14,153.06 | 13,080.35 | 10,866.95 | 51,031.24 |
| 2 | SEGMENT RESULTS (Profit/(Loss) before tax and interest) <br> a) Manufacturing (CRAMS) <br> b) Services (DDDSS) <br> c) Research \& Development | $\begin{array}{r} 6,731.05 \\ 34.89 \\ (1,241.35) \\ \hline \end{array}$ | $\begin{array}{r} 5,937.20 \\ 200.73 \\ (1,238.05) \\ \hline \end{array}$ | $\begin{array}{r} 5,179.70 \\ 15.83 \\ (793.87) \\ \hline \end{array}$ | $\begin{array}{r} 26,308.56 \\ 888.72 \\ (4,794.79) \\ \hline \end{array}$ |
|  | TOTAL | 5,524.59 | 4,899.88 | 4,401.66 | 22,402.49 |
|  | Less: (i) Interest <br> (ii) Other Un-allocable expenses net off <br> (iii) un-allocable Income | $\begin{array}{r} \hline 77.56 \\ 312.20 \end{array}$ | $\begin{array}{r} \hline 89.44 \\ 343.47 \end{array}$ | $\begin{array}{r} \hline 217.43 \\ 94.04 \end{array}$ | $\begin{array}{r} \hline 618.92 \\ 1,509.78 \end{array}$ |
|  | Profit Before Tax | 5,134.83 | 4,466.97 | 4,090.19 | 20,273.79 |
| 3 | CAPITAL EMPLOYED (Segment Assets - Segment Liabilities) <br> a) Manufacturing (CRAMS) <br> b) Services (DDDSS) <br> c) Research \& Development <br> d) Net assets which are not segmented and used commonly | $\begin{array}{r} 22,445.39 \\ 3,371.36 \\ 1,198.81 \\ 2,429.38 \\ \hline \end{array}$ | $\begin{array}{r} 19,509.25 \\ 3,493.63 \\ 1,815.26 \\ 1,626.50 \\ \hline \end{array}$ | $\begin{array}{r} 17,627.07 \\ 3,286.00 \\ 2,684.65 \\ 787.01 \\ \hline \end{array}$ | $\begin{array}{r} 19,509.25 \\ 3,493.63 \\ 1,815.26 \\ 1,626.50 \\ \hline \end{array}$ |
|  | TOTAL | 29,444.94 | 26,444.64 | 24,384.73 | 26,444.64 |

Notes:

1) The above Un-audited results were approved and taken on record at the Board of Directors' Meeting held on 12th August, 2014.
2) Previous year(s) figures have been regrouped/reclassified whenever necessary.
${ }^{3)}$ The depreciation has been computed as per Schedule II of the Companies Act 2013 effective April 1, 2014. Accordingly the depreciation for the qtr ended 30/06/2014 is higher by Rs. 405.99 Lakhs shown as exceptional item. Further, based on transitional provision in note 7(b) of schedule II an amount of Rs. 473.50 Lakhs (net of defrerred tax of Rs. 243.81 Lakhs) has been adjusted with the opening Reserves.
3) The above results are reviewed by Statutory Auditors.

For SUVEN LIFE SCIENCES LTD

